Price erosion, weak demand for acute portfolio and low ANDA approvals in the US weighed on the performance of Indian pharma in Q1FY22. However, the scenario is expected to change in H2FY22 when new approvals and inspections resume
Through the Sehat Sathi App business can access unsecured business loans at low interest
Results from year two of the pivotal Phase 3 KITE clinical trial reaffirmed visual acuity gains and fluid reduction findings as well as safety profile from year one
TAH is now undergoing regulatory clearance and final quality control procedures for the swab deployment in India, EU, Singapore, UK, US, Australia and others for COVID-19 testing
India’s dependency on China for pharma intermediates can change if there is a proper coordination between educational institutes, research institutes and pharma manufacturers
InferVision's AI applications have been developed to quickly and accurately analyse signs of pulmonary infections from regular chest CT images. These images are processed to indicate ground-glass opacity and high tissue density, which are key findings of viral pneumonia caused by the coronavirus
National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
The data suggest that a booster dose given within 6 to 12 months after the second dose may help maintain a high level of protection against COVID-19.
This multi-centre study (sites in the US and Europe) comprising about 387 patients is likely to be completed in about 36 months and the topline result is expected by the end of 2024
Brivaracetam tablets are indicated for the treatment of partial-onset seizures in patients four years of age and older
Subscribe To Our Newsletter & Stay Updated
